



## Immune-Related Adverse Effects of Checkpoint Inhibitors in Cancer Patients

Guest Editor:

**Prof. Dr. Christof Vulsteke**

Integrated Cancer Center Ghent,  
AZ Maria Middelaers, Buitenring  
Sint Denijs 30, 9000 Ghent,  
Belgium

Deadline for manuscript  
submissions:

**closed (20 April 2024)**

### Message from the Guest Editor

Dear Colleagues,

The development of Immune Checkpoint Inhibitors (ICIs) has significantly altered the field of oncology by achieving durable anti-tumor responses in a number of advanced malignancies with a previously poor prognosis. Currently, up to 50% of all cancer patients can potentially benefit from treatment with ICIs. As opposed to conventional anti-cancer therapies, characterized by acute onset emetic and myelosuppressive effects, ICIs exhibit a favorable side effect profile. Nevertheless, their increased use over the last few years has led to the discovery of a distinct set of adverse events, i.e., immune-related adverse events (irAEs). Approximately 50% of the patients who receive ICI treatment will experience some kind of irAE. Immune-related cardiovascular adverse events have gained significant interest over the past decade. Although they were initially thought to be rare, the increasing use of ICIs in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of both acute and chronic cardiovascular irAEs. In this Special Issue, we focus on the cardiovascular-related adverse events of ICIs.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

## Contact Us

---

*Pharmaceuticals* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)  
[X@Pharmaceut\\_MDPI](https://twitter.com/Pharmaceut_MDPI)